Kodiak Sciences Q3 EPS Forecast Boosted by Zacks Research

Kodiak Sciences Inc. (NASDAQ:KOD) – Stock analysts at Zacks Research increased their Q3 2025 earnings per share estimates for shares of Kodiak Sciences in a report issued on Tuesday, October 22nd. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of ($1.10) for the quarter, up from their prior estimate of ($1.13). The consensus estimate for Kodiak Sciences’ current full-year earnings is ($3.52) per share. Zacks Research also issued estimates for Kodiak Sciences’ Q4 2025 earnings at ($1.17) EPS, FY2025 earnings at ($4.00) EPS, Q1 2026 earnings at ($0.93) EPS, Q2 2026 earnings at ($0.85) EPS, Q3 2026 earnings at ($1.04) EPS and FY2026 earnings at ($3.82) EPS.

Separately, HC Wainwright reaffirmed a “neutral” rating and set a $3.00 target price on shares of Kodiak Sciences in a research report on Tuesday, September 24th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $5.00.

Kodiak Sciences Price Performance

KOD stock opened at $3.74 on Friday. Kodiak Sciences has a 1-year low of $1.37 and a 1-year high of $7.77. The business has a 50-day moving average price of $2.76 and a 200 day moving average price of $2.95. The company has a market capitalization of $196.48 million, a P/E ratio of -0.84 and a beta of 2.34.

Kodiak Sciences (NASDAQ:KOD) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.86) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.01.

Institutional Investors Weigh In On Kodiak Sciences

Institutional investors and hedge funds have recently modified their holdings of the company. SG Americas Securities LLC acquired a new stake in shares of Kodiak Sciences in the third quarter worth $33,000. Sanctuary Advisors LLC acquired a new stake in Kodiak Sciences during the 2nd quarter worth about $36,000. Squarepoint Ops LLC purchased a new position in shares of Kodiak Sciences during the 2nd quarter valued at about $127,000. Marshall Wace LLP lifted its holdings in shares of Kodiak Sciences by 41.6% in the 2nd quarter. Marshall Wace LLP now owns 166,425 shares of the company’s stock valued at $391,000 after buying an additional 48,930 shares during the period. Finally, Sei Investments Co. boosted its stake in shares of Kodiak Sciences by 27.1% in the second quarter. Sei Investments Co. now owns 143,841 shares of the company’s stock worth $338,000 after buying an additional 30,683 shares during the last quarter. Institutional investors and hedge funds own 89.06% of the company’s stock.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.